Literature DB >> 9802941

An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications.

R H Weisbart1, M Stempniak, S Harris, D J Zack, K Ferreri.   

Abstract

A murine monoclonal anti-dsDNA antibody was found to penetrate living cells and localize in the nucleus without pathologic effects. A single mutation in VH markedly enhanced cellular penetration. The mutant antibody was produced as recombinant Fab and single chain antibody fragments to investigate its use as a delivery system to target the cell nucleus. Complexes were made containing Fab fragments and alkaline phosphatase conjugated goat antibodies to mouse |gk chains. Fab fragments transported 305 kDa goat antibody-enzyme complexes into the nucleus in COS-7 and CHO cells. A single chain antibody cDNA was constructed by splice overlap extension PCR and expressed in COS-7 cells. Binding of the single chain antibody to dsDNA was shown by ELISA, and cellular penetration and nuclear localization were demonstrated in COS-7 and CHO cells. The single chain antibody cDNA was ligated into the expression vector, pEGFP, to produce a fusion protein with green fluorescent protein. The fusion protein penetrated COS-7 cells and localized in the cell nucleus. The single chain antibody produced during sustained expression in CHO cells re-entered antibody-producing cells and localized in the nucleus without affecting cell viability. Our results demonstrate the potential use of a modified autoantibody as a delivery system to target the cell nucleus. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802941     DOI: 10.1006/jaut.1998.0212

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  17 in total

1.  The predestination of autoantibodies.

Authors:  D Alarcón-Segovia
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.

Authors:  Haiqing Yi; Tao Sun; Dustin Armstrong; Scott Borneman; Chunyu Yang; Stephanie Austin; Priya S Kishnani; Baodong Sun
Journal:  J Mol Med (Berl)       Date:  2017-02-02       Impact factor: 4.599

3.  Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors:  M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-07-25       Impact factor: 27.287

4.  Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease.

Authors:  Grant L Austin; Zoe R Simmons; Jack E Klier; Alberto Rondon; Brad L Hodges; Robert Shaffer; Nadine M Aziz; Tracy R McKnight; James R Pauly; Dustin D Armstrong; Craig W Vander Kooi; Matthew S Gentry
Journal:  Mol Pharm       Date:  2019-08-02       Impact factor: 4.939

Review 5.  Targeted heat shock protein 72 for pulmonary cytoprotection.

Authors:  Missag H Parseghian; Stephen T Hobson; Richard A Richieri
Journal:  Ann N Y Acad Sci       Date:  2016-05-06       Impact factor: 5.691

6.  Cardioprotective Effects of HSP72 Administration on Ischemia-Reperfusion Injury.

Authors:  Takashi Tanimoto; Missag H Parseghian; Takehiro Nakahara; Hideki Kawai; Navneet Narula; Dongbin Kim; Robert Nishimura; Richard H Weisbart; Grace Chan; Richard A Richieri; Nezam Haider; Farhan Chaudhry; Glenn T Reynolds; John Billimek; Francis G Blankenberg; Partho P Sengupta; Artiom D Petrov; Takashi Akasaka; H William Strauss; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2017-09-19       Impact factor: 24.094

7.  Nuclear-targeting autoantibodies induced nuclear PARP cleavage accompanied by more pronounced decrease of peripheral white blood cells than Ro/SSA and La/SSB antigen-targeting autoantibodies.

Authors:  Ingrid Böhm
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

8.  Tumor suppressor and T-regulatory functions of Foxp3 are mediated through separate signaling pathways.

Authors:  Emil Heinze; Grace Chan; Rachel Mory; Raz Khavari; Asif Alavi; Sue Y Chung; Robert N Nishimura; Richard H Weisbart
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

9.  An anti-nucleic acid antibody delivers antigen to the cross-presentation pathway in dendritic cells and potentiates therapeutic antitumor effects.

Authors:  Chuong D Pham; Min-Yeong Woo; Yong-Sung Kim; Sun Park; Myung-Hee Kwon
Journal:  J Immunol       Date:  2012-11-14       Impact factor: 5.422

10.  Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy.

Authors:  Michael W Lawlor; Dustin Armstrong; Marissa G Viola; Jeffrey J Widrick; Hui Meng; Robert W Grange; Martin K Childers; Cynthia P Hsu; Michael O'Callaghan; Christopher R Pierson; Anna Buj-Bello; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2013-01-09       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.